Literature DB >> 2366566

Influence of corticosteroid-free maintenance immunosuppression on allograft coronary artery disease after cardiac transplantation.

R M Ratkovec1, R B Wray, D G Renlund, J B O'Connell, M R Bristow, W A Gay, S V Karwande, D B Doty, R C Millar, R L Menlove.   

Abstract

Although the etiology of allograft coronary artery disease, a major limiting factor in long-term survival after cardiac transplantation, is poorly understood, it is undoubtedly in part immune mediated and not detected by routine endomyocardial biopsy. Therefore it is possible that withdrawal of maintenance corticosteroids, although providing other short- and long-term benefits, could increase the prevalence of allograft coronary artery disease by permitting undetected immune-mediated vascular injury to occur. To assess whether corticosteroid-free maintenance immunosuppression increased the prevalence of allograft coronary artery disease, we reviewed serial angiograms of 102 patients (49% not receiving corticosteroid maintenance therapy) who underwent heart transplantation after March 7, 1985. Multiple variables including serum cholesterol, recipient and donor age, sex, blood pressure, rejection frequency and severity, early rejection prophylaxis protocol (polyclonal versus monoclonal T-cell agents), and corticosteroid use were examined in relation to allograft coronary artery disease by univariate and multivariate analyses. Allograft coronary artery disease was identified in 21 patients (seven severe, four moderate, and 10 mild). The prevalence by Kaplan-Meier life-table analysis was 17% at 1 year and 25% at 2 years. No further allograft coronary artery disease was detected among patients undergoing angiography at three years. Increased allograft coronary artery disease was not noted in patients withdrawn from maintenance corticosteroids when compared with their corticosteroid-requiring counterparts. In fact, with each 1 gm increment in cumulative corticosteroid use, a slightly increased risk (1.04, p less than 0.05) of allograft coronary artery disease was noted (Cox regression model). None of the other variables correlated with the prevalence of allograft coronary artery disease. Thus withdrawal of maintenance corticosteroids is not associated with an increased risk of early allograft coronary artery disease and minimization of corticosteroids may lead to a decreased long-term incidence of coronary artery disease in cardiac transplant recipients.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2366566

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  6 in total

1.  Ten year survival after heart transplantation: palliative procedure or successful long term treatment?

Authors:  S Fraund; K Pethig; U Franke; T Wahlers; W Harringer; J Cremer; H G Fieguth; P Oppelt; A Haverich
Journal:  Heart       Date:  1999-07       Impact factor: 5.994

2.  Coronary artery disease after heart transplantation: clinical aspects.

Authors:  C D Scott; J H Dark
Journal:  Br Heart J       Date:  1992-09

3.  Coronary occlusive disease and late graft failure after cardiac transplantation.

Authors:  P A Mullins; N R Cary; L Sharples; J Scott; D Aravot; S R Large; J Wallwork; P M Schofield
Journal:  Br Heart J       Date:  1992-09

4.  Impairment of coronary flow reserve in orthotopic cardiac transplant recipients with minor coronary occlusive disease.

Authors:  P A Mullins; A Chauhan; L Sharples; N R Cary; S R Large; J Wallwork; P M Schofield
Journal:  Br Heart J       Date:  1992-09

5.  Paediatric cardiac transplantation with steroid-sparing maintenance immunosuppression.

Authors:  J Au; J W Gregory; I W Colquhoun; C D Scott; C J Hilton; S Hunter; J H Dark
Journal:  Arch Dis Child       Date:  1992-10       Impact factor: 3.791

Review 6.  Steroid-free and steroid withdrawal protocols in heart transplantation: the review of literature.

Authors:  Massimo Baraldo; Giorgia Gregoraci; Ugolino Livi
Journal:  Transpl Int       Date:  2014-04-12       Impact factor: 3.782

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.